Groundbreaking Innovation from Singapore's Premier University
The National University of Singapore (NUS) has unveiled a pioneering treatment for dry eye disease that draws directly from the photosynthetic machinery of spinach plants. This light-activated approach, developed by researchers in the College of Design and Engineering, represents a significant advancement in biomedical engineering and offers new hope for millions affected by this common condition.
Understanding Dry Eye Disease and Its Global Burden
Dry eye disease, often abbreviated as DED, occurs when the eyes do not produce enough tears or when the tears evaporate too quickly. This leads to inflammation, discomfort, and potential damage to the corneal surface. Symptoms include irritation, redness, blurred vision, and a gritty sensation. The condition affects an estimated 1.5 billion people worldwide, making it one of the most prevalent ocular disorders.
In Singapore and across Asia, rising screen time, air-conditioned environments, and aging populations contribute to higher incidence rates. Traditional treatments such as artificial tears provide temporary relief but do not address the underlying oxidative stress that depletes essential molecules like NADPH in corneal cells.
The Science of LEAF: Transplanting Plant Photosynthesis into Human Eyes
At the heart of the NUS breakthrough lies LEAF, short for Light-reaction Enriched thylAkoid NADPH-Foundry. This nanosized construct consists of structurally preserved thylakoid grana extracted from spinach leaves. Thylakoid grana are the membrane compartments inside plant chloroplasts where light energy is converted into chemical energy, specifically producing NADPH.
The NUS team engineered these particles to approximately 400 nanometres in size, allowing them to be readily absorbed by corneal cells. Once inside, the particles harness ambient indoor light—the same light used for vision—to generate NADPH independently of the cell's own pathways. This restores the antioxidant balance disrupted in dry eye disease.
The extraction process uses a patented mild mechanical and chemical method that preserves the functional integrity of the photosynthetic membranes while ensuring biocompatibility for human use.
Development Led by NUS Chemical and Biomolecular Engineering Experts
The research was spearheaded by Associate Professor David Leong Tai Wei from the Department of Chemical and Biomolecular Engineering at NUS. Collaborators included biomolecular engineer Xing Kuoran and other team members within the College of Design and Engineering.
This project exemplifies the interdisciplinary strengths of Singapore's higher education institutions, combining plant biology, nanotechnology, and ophthalmology. NUS's commitment to translational research has positioned it as a leader in applying fundamental science to real-world medical challenges.
Photo by chiara conti on Unsplash
Preclinical Results Show Rapid and Superior Outcomes
In laboratory tests using human corneal cells and mouse models engineered to mimic dry eye disease, the LEAF treatment demonstrated remarkable efficacy. Mice treated with the spinach-derived eye drops twice daily for five days showed reversal of corneal damage to near-healthy levels.
Importantly, LEAF outperformed the commonly prescribed medication cyclosporine A (marketed as Restasis) in head-to-head comparisons. The treatment also reduced harmful oxidants in tear samples from patients, suggesting broader applicability.
No adverse effects were observed in the preclinical studies, highlighting the safety profile of this plant-derived approach.
Key Advantages of the Spinach-Derived Eye Drops
Unlike existing therapies that often require frequent application or invasive procedures, the NUS innovation offers several distinct benefits. It is delivered as a simple eye drop, requires no external device or power source, and utilizes ordinary ambient light.
Because it is derived from a common food source like spinach, the treatment carries strong potential for clinical translation and regulatory approval. This approach marks the first successful application of photosynthesis in mammalian tissue, opening entirely new avenues for treating oxidative stress-related conditions beyond the eye.
Implications for Singapore's Higher Education and Research Ecosystem
This development underscores the vital role of institutions like NUS in driving biomedical innovation within Singapore. The College of Design and Engineering continues to attract top talent and foster collaborations that bridge engineering with life sciences.
For PhD-track students and early-career researchers, projects like LEAF highlight opportunities in translational nanotechnology and regenerative medicine. Singapore's emphasis on research excellence supports such breakthroughs, contributing to the nation's reputation as a global hub for science and technology.
Pathway to Clinical Trials and Broader Applications
The NUS team has expressed confidence in the technology's readiness for clinical translation. Plans are underway to advance LEAF toward human trials, with potential applications extending to other conditions involving oxidative damage or NADPH deficiency.
Stakeholders in Singapore's healthcare and education sectors view this as a model for how university research can directly benefit patients while enhancing the country's knowledge economy.
Photo by Elly Brian on Unsplash
Future Outlook for Light-Activated Therapies
Looking ahead, the success of LEAF could inspire similar bio-inspired treatments worldwide. Researchers anticipate further refinements to optimize delivery, dosage, and long-term effects.
As Singapore continues to invest in higher education and research infrastructure, breakthroughs like this position local universities at the forefront of solving global health challenges through innovative, sustainable approaches.
Opportunities for Academics and Job Seekers in Related Fields
The NUS achievement creates ripple effects across academic careers in chemical engineering, ophthalmology, and materials science. Universities and research institutes in Singapore actively seek faculty, postdoctoral fellows, and research assistants to build on such foundational work.
Professionals interested in contributing to next-generation therapies will find Singapore's ecosystem particularly supportive, with strong linkages between academia, industry, and clinical practice.